{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:08:22Z","timestamp":1790842102384,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"am","delay-in-days":319,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pharmthera.2023.108506","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T22:06:25Z","timestamp":1691532385000},"page":"108506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Therapeutic targeting of the pituitary tumor microenvironment"],"prefix":"10.1016","volume":"250","author":[{"given":"Mirela-Diana","family":"Ilie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"De Alcubierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lucia","family":"Carretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Jouanneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Raverot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0005","doi-asserted-by":"crossref","DOI":"10.1007\/s12022-019-9568-5","article-title":"An institutional experience of tumor progression to pituitary carcinoma in a 15-year cohort of 1055 consecutive pituitary neuroendocrine tumors","volume":"30","author":"Alshaikh","year":"2019","journal-title":"Endocrine Pathology"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0010","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.16.2.253","article-title":"Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells","author":"Banerjee","year":"2000","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0015","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1038\/s41388-019-0779-5","article-title":"Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors","volume":"38","author":"Barry","year":"2019","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108506_bb0020","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.863850","article-title":"Targeting Integrins for Cancer therapy\u2014Disappointments and opportunities","volume":"10","author":"Bergonzini","year":"2022","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108506_bb0030","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"European Journal of Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","article-title":"Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab","volume":"31","author":"Caccese","year":"2020","journal-title":"Anti-Cancer Drugs"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0040","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocrine-Related Cancer"},{"issue":"`1","key":"10.1016\/j.pharmthera.2023.108506_bb0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.gendis.2014.12.002","article-title":"Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas","volume":"2","author":"Cathcart","year":"2015","journal-title":"Genes & Diseases"},{"issue":"51","key":"10.1016\/j.pharmthera.2023.108506_bb0050","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1108696108","article-title":"Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells","volume":"108","author":"Chakroborty","year":"2011","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108506_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.30628","article-title":"Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model: Tumoral vessel normalization by dopamine and Vegf blockade","volume":"140","author":"Chauvet","year":"2017","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: Targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nature Reviews Drug Discovery"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/joim.12019","article-title":"VEGFA and tumour angiogenesis","volume":"273","author":"Claesson-Welsh","year":"2013","journal-title":"Journal of Internal Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0070","doi-asserted-by":"crossref","DOI":"10.4081\/ejh.2019.3010","article-title":"VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas","volume":"63","author":"Corlan","year":"2019","journal-title":"European Journal of Histochemistry"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/608497","article-title":"Angiogenesis in pituitary adenomas: Human studies and new mutant mouse models","volume":"2014","author":"Cristina","year":"2014","journal-title":"International Journal of Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti\u2013PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0085","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in Corticotroph and Lactotroph aggressive tumors and carcinomas: Two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"Journal of Personalized Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108506_bb0090","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2019-00432","article-title":"Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant treatment of an AIP Mutation\u2013Positive Child","volume":"104","author":"Dutta","year":"2019","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"17","key":"10.1016\/j.pharmthera.2023.108506_bb0095","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.3390\/cancers14174093","article-title":"Immunotherapy for aggressive and metastatic pituitary neuroendocrine tumors (PitNETs): State-of-the art","volume":"14","author":"Feola","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0100","article-title":"Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy","author":"Goichot","year":"2021","journal-title":"Clinical Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108506_bb0105","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108506_bb0110","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-09-1977","article-title":"Complementary actions of inhibitors of Angiopoietin-2 and VEGF on tumor angiogenesis and growth","volume":"70","author":"Hashizume","year":"2010","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0115","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ecl.2020.05.008","article-title":"Aggressive pituitary adenomas and carcinomas","volume":"49","author":"Ilie","year":"2020","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108506_bb0120","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa497","article-title":"Treatment options for gonadotroph tumors: Current state and perspectives","volume":"105","author":"Ilie","year":"2020","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/endrev\/bnac024","article-title":"Biological and therapeutic implications of the tumor microenvironment in pituitary adenomas","volume":"44","author":"Ilie","year":"2023","journal-title":"Endocrine Reviews"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108506_bb0130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1530\/ERC-22-0037","article-title":"Immunotherapy in aggressive pituitary tumors and carcinomas: A systematic review","volume":"29","author":"Ilie","year":"2022","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0135","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: A cohort study","author":"Ilie","year":"2022","journal-title":"European Journal of Endocrinology"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108506_bb0140","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(10)70232-1","article-title":"Biomarkers to predict the clinical efficacy of bevacizumab in cancer","volume":"11","author":"Jubb","year":"2010","journal-title":"The Lancet Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0145","doi-asserted-by":"crossref","DOI":"10.1007\/BF02739874","article-title":"Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study","volume":"6","author":"Jugenburg","year":"1995","journal-title":"Endocrine Pathology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108506_bb0150","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114364","article-title":"Angpt2\/Tie2 autostimulatory loop controls tumorigenesis","volume":"14","author":"Karabid","year":"2022","journal-title":"EMBO Molecular Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108506_bb0155","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-3486","article-title":"Targeting PD-L1 initiates effective antitumor immunity in a murine model of Cushing disease","volume":"26","author":"Kemeny","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0160","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1038\/s41598-021-81914-0","article-title":"Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer","volume":"11","author":"Kr\u00fcger","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/623092","article-title":"Temozolomide-induced shrinkage of invasive pituitary adenoma in patient with Nelson\u2019s syndrome: A case report and review of the literature","volume":"2015","author":"Kurowska","year":"2015","journal-title":"Case Reports in Endocrinology"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.576027","article-title":"Case report: A case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy","volume":"11","author":"Lamb","year":"2020","journal-title":"Frontiers in Endocrinology"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108506_bb0175","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO.2012.46.2762","article-title":"Markers of response for the antiangiogenic agent bevacizumab","volume":"31","author":"Lambrechts","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108506_bb0180","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/jc.2018-01347","article-title":"Marked response of a Hypermutated ACTH-secreting pituitary carcinoma to Ipilimumab and Nivolumab","volume":"103","author":"Lin","year":"2018","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108506_bb0185","doi-asserted-by":"crossref","first-page":"bvab133","DOI":"10.1210\/jendso\/bvab133","article-title":"Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma","volume":"5","author":"Lin","year":"2021","journal-title":"Journal of the Endocrine Society"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0190","doi-asserted-by":"crossref","DOI":"10.1007\/BF02738884","article-title":"Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas","volume":"10","author":"Lloyd","year":"1999","journal-title":"Endocrine Pathology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0195","doi-asserted-by":"crossref","DOI":"10.1007\/s12022-015-9383-6","article-title":"Immune cell infiltrates in pituitary adenomas: More macrophages in larger adenomas and more T cells in growth hormone adenomas","volume":"26","author":"Lu","year":"2015","journal-title":"Endocrine Pathology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0200","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12022-015-9383-6","article-title":"Immune cell infiltrates in pituitary adenomas: More macrophages in larger adenomas and more T cells in growth hormone adenomas","volume":"26","author":"Lu","year":"2015","journal-title":"Endocrine Pathology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0205","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1210\/jc.2009-1583","article-title":"Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma","volume":"95","author":"Lupi","year":"2010","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"24","key":"10.1016\/j.pharmthera.2023.108506_bb0210","doi-asserted-by":"crossref","first-page":"15585","DOI":"10.3390\/ijms232415585","article-title":"The VEGF\/VEGFR Axis revisited: Implications for cancer therapy","volume":"23","author":"Mabeta","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001532","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: Report of four cases from a phase II study","volume":"8","author":"Majd","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0220","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-019-0830-3","article-title":"Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours","volume":"7","author":"Marques","year":"2019","journal-title":"Acta Neuropathologica Communications"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108506_bb0225","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1530\/ERC-19-0327","article-title":"Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness","volume":"26","author":"Marques","year":"2019","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2020.100852","article-title":"The tumour microenvironment of pituitary neuroendocrine tumours","volume":"58","author":"Marques","year":"2020","journal-title":"Frontiers in Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0235","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11102-022-01211-5","article-title":"The microenvironment of pituitary adenomas: Biological, clinical and therapeutical implications","volume":"25","author":"Marques","year":"2022","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0240","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11154-022-09777-y","article-title":"The hallmarks of cancer\u2026 in pituitary tumors?","volume":"24","author":"Marrero-Rodr\u00edguez","year":"2023","journal-title":"Reviews in Endocrine & Metabolic Disorders"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0245","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: Results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"European Journal of Endocrinology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0250","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-020-01114-3","article-title":"Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression","volume":"24","author":"Mei","year":"2021","journal-title":"Pituitary"},{"issue":"47","key":"10.1016\/j.pharmthera.2023.108506_bb0255","doi-asserted-by":"crossref","first-page":"76565","DOI":"10.18632\/oncotarget.12088","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","author":"Mei","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108506_bb9091","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/ajco.13365","article-title":"The adverse events associated with combination immunotherapy in cancers: Challenges and chances","volume":"16","author":"Zhuo","year":"2020","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"15_suppl","key":"10.1016\/j.pharmthera.2023.108506_bb0260","article-title":"Metastatic ACTH-producing pituitary carcinoma managed with combination pasireotide and bevacizumab following failure of temozolamide therapy: A case report","volume":"31","author":"O\u2019Riordan","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0265","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-011-0346-8","article-title":"Anti-VEGF therapy in pituitary carcinoma","volume":"15","author":"Ortiz","year":"2012","journal-title":"Pituitary"},{"issue":"03","key":"10.1016\/j.pharmthera.2023.108506_bb0270","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/a-1260-3975","article-title":"Bevacizumab in aggressive pituitary adenomas \u2013 Experience with 3 patients","volume":"129","author":"Osterhage","year":"2021","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0275","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF02738785","article-title":"Immunocytochemical investigations on the vascularization of pituitary adenomas","volume":"8","author":"Pawlikowski","year":"1997","journal-title":"Endocrine Pathology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0280","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11102-012-0421-9","article-title":"Enhanced nestin expression and small blood vessels in human pituitary adenomas","volume":"16","author":"Perez-Millan","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0285","article-title":"Clinical relevance of tumour-associated macrophages","author":"Pittet","year":"2022","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0290","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa520","article-title":"Immune landscape of pituitary neuroendocrine Tumours reveals association between macrophages and Gonadotroph-tumour invasion","author":"Principe","year":"2020","journal-title":"The Journal of Clinical Endocrinology & Metabolism."},{"issue":"18","key":"10.1016\/j.pharmthera.2023.108506_bb0295","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0300","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0305","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"European Journal of Endocrinology"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108506_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101712","article-title":"Immunotherapy in pituitary carcinomas and aggressive pituitary tumors","volume":"36","author":"Raverot","year":"2022","journal-title":"Best Practice & Research Clinical Endocrinology & Metabolism"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108506_bb0315","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nature Reviews Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0320","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0325","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.wneu.2018.11.011","article-title":"Long-term survival after transformation of an Adrenocorticotropic Hormone\u2013Secreting pituitary Macroadenoma to a silent Corticotroph Pituitary Carcinoma","volume":"122","author":"Rotman","year":"2019","journal-title":"World Neurosurgery"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108506_bb0330","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4149\/neo_2010_06_590","article-title":"Endoglin and CD-34 immunoreactivity in the assessment of microvessel density in normal pituitary and adenoma subtypes","volume":"57","author":"Rotondo","year":"2010","journal-title":"Neoplasma"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0335","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11102-012-0434-4","article-title":"Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence","volume":"16","author":"S\u00e1nchez-Ortiga","year":"2013","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108506_bb0340","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/jcm8050695","article-title":"Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors","volume":"8","author":"Sato","year":"2019","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0345","doi-asserted-by":"crossref","DOI":"10.1227\/neu.0000000000002024","article-title":"Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: A case report","author":"Shah","year":"2022","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0350","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack","year":"2022","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0355","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-20-0151","article-title":"Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: A new emerging treatment?","volume":"184","author":"Sol","year":"2020","journal-title":"European Journal of Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108506_bb0360","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1530\/eje.0.1490455","article-title":"Functional in vitro studies on the role and regulation of interleukin-6 in human somatotroph pituitary adenomas","volume":"149","author":"Thiele","year":"2003","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0365","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocn.2017.02.052","article-title":"Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection","volume":"41","author":"Touma","year":"2017","journal-title":"Journal of Clinical Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0370","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s12022-021-09673-2","article-title":"PD-L1 is preferentially expressed in PIT-1 positive pituitary neuroendocrine Tumours","volume":"32","author":"Turchini","year":"2021","journal-title":"Endocrine Pathology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0375","doi-asserted-by":"crossref","DOI":"10.1210\/jcem.85.3.6485","article-title":"Angiogenesis in pituitary adenomas and the Normal pituitary gland","volume":"85","author":"Turner","year":"2000","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108506_bb0380","doi-asserted-by":"crossref","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: Alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108506_bb0385","doi-asserted-by":"crossref","DOI":"10.1007\/s004280000373","article-title":"Microvessel density in pituitary adenomas and carcinomas","volume":"438","author":"Vidal","year":"2001","journal-title":"Virchows Archiv"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0390","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ghir.2011.03.005","article-title":"Interleukin-8 production from human somatotroph adenoma cells is stimulated by interleukin-1\u03b2 and inhibited by growth hormone releasing hormone and somatostatin","volume":"21","author":"Vindel\u00f8v","year":"2011","journal-title":"Growth Hormone & IGF Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0395","doi-asserted-by":"crossref","first-page":"Article 1","DOI":"10.1007\/s11060-018-2844-2","article-title":"The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy","volume":"139","author":"Wang","year":"2018","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0400","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.wneu.2018.12.174","article-title":"Apatinib (YN968D1) and Temozolomide in recurrent invasive pituitary adenoma: Case report and literature review","volume":"124","author":"Wang","year":"2019","journal-title":"World Neurosurgery"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108506_bb0405","doi-asserted-by":"crossref","first-page":"e3207","DOI":"10.1210\/clinem\/dgaa449","article-title":"The immune profile of pituitary adenomas and a novel immune classification for predicting immunotherapy responsiveness","volume":"105","author":"Wang","year":"2020","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0410","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12766","article-title":"Immune checkpoint inhibitors: The linchpins of modern immunotherapy","volume":"290","author":"Wilky","year":"2019","journal-title":"Immunological Reviews"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0415","doi-asserted-by":"crossref","first-page":"192","DOI":"10.7150\/ijbs.7770","article-title":"CDK5 and its activator P35 in Normal pituitary and in pituitary adenomas: Relationship to VEGF expression","volume":"10","author":"Xie","year":"2014","journal-title":"International Journal of Biological Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108506_bb0420","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v11.i2.91","article-title":"Pituitary carcinoma: Two case reports and review of literature","volume":"11","author":"Xu","year":"2020","journal-title":"World Journal of Clinical Oncology"},{"issue":"22","key":"10.1016\/j.pharmthera.2023.108506_bb0425","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.18632\/oncotarget.26775","article-title":"Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes","volume":"10","author":"Yagnik","year":"2019","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108506_bb0430","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.tips.2018.06.003","article-title":"MMP-responsive \u201csmart\u201d drug delivery and tumor targeting","volume":"39","author":"Yao","year":"2018","journal-title":"Trends in Pharmacological Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108506_bb0435","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11060-020-03476-x","article-title":"In silico analysis of the immunological landscape of pituitary adenomas","volume":"147","author":"Yeung","year":"2020","journal-title":"Journal of Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0440","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1677\/ERC-06-0026","article-title":"Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion","volume":"14","author":"Zatelli","year":"2007","journal-title":"Endocrine-Related Cancer"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108506_bb0445","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.7150\/thno.53749","article-title":"Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108506_bb0450","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/JTO.0b013e31823085f4","article-title":"Predictive value of Intratumoral microvascular density in patients with advanced non-small cell lung Cancer receiving chemotherapy plus bevacizumab","volume":"7","author":"Zhao","year":"2012","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.pharmthera.2023.108506_bb0455","article-title":"Sprouting angiogenesis in human pituitary adenomas","volume":"12","author":"Zhou","year":"2022","journal-title":"Frontiers in Oncology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:33:21Z","timestamp":1759012401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823001705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":92,"alternative-id":["S0163725823001705"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108506","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of the pituitary tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108506"}}